U.S. House · 117th Congress · H.R. 7473
Generic Substitution Noninterference Act
To prohibit pharmaceutical manufacturers from interfering with therapeutically equivalent or interchangeable substitution decisions by health care providers to limit competition from a generic drug or biosimilar biological product, and for other purposes.
Follow
Log in to follow this bill and get an email when there’s a new vote (premium).
- Sponsor
- Carolyn B. MaloneyD-NY-12
- Introduced
- April 7, 2022, in the House
- Issue areas
- Policy area
- Health (from the Congressional Research Service)
- Full text and actions
- congress.gov
Votes on this bill (0)
Neither the House nor the Senate has held a roll-call vote on this bill.
Cosponsors (7)
7 Democrats. Each member is shown with the party they were counted with on the day they signed on. How we count these
Original cosponsors
- David N. CicillineD-RI-1
- Mark DeSaulnierD-CA-11
- Jerrold NadlerD-NY-10
- Katie PorterD-CA-45
- Jamie RaskinD-MD-8
- Janice D. SchakowskyD-IL-9
- Peter WelchD-VT-AL